I
n ea rl y t 993, the USP Subcomrnittce o n Di ssolution an d Bioava ila bili ty (DBA) decided that the soft ge la tin capsul es dissolution test exemption in the US P <7 11 > Dissoluti o n General C hapter sho uld be de leted. It was determined that there shou ld be" dissolution test for all types of capsules. For ca psules where a dissolution test could not be develo ped, a rupture test was proposed in Pharmacopeia l Forum (PF), the revision jou rn al of the USP.
In Jul y 1993, at a DBA Subcommittee meeting it was decided dlat "aged capsules" that did not pass the dissolution test would undergo a second dissoluti o n test us in g medi um co ntaining enzyme .
Ilowcvcr, this was only .1 11 owed providing that the re was no ev id ence thnt the bioavailabilty of the capsul es had been adversely changed. The change was proposed in the USP <7 1 I> Dissolution Gene ral C hapte r in the Previews section of the PF in ea rl y 1994. This was a fairly stringent standard, requ.irin g in most cases a bi oequi valence snldy, and objections were raised by the phann3ceurical industry.
At this point, the FDA/Industry Gelatin Ca psul es Wo rkin g Gro up was formed and USP became a participant. The USP DBA Subcommittee d ec id ed to defer the "aged ca psules" proposa l until the Wo rkin g G ro up had completed it, bioequivaIc nce stud ies. The bioequivalence studies showed that the stressed hard gelati n ca psules were biocquivalent to unstressed C:lpsu lcs.
In to the specification upon testing in o ne of th ese media is acceptable." 'T'herc are certa in aspects of the proposal that shou ld be noted. It does not address the lise of SUffacranLS. The product ca n fail any time-that is even at release. I [owever, the a nal yst should be warned that if t he product fa ils at the time of rclcasc--on stabi lity the <lddcd enzyme may not be sufficient to overcome the crosslinking problem.
This propos:ll W,-lS adoptcd:ls an [ntc rilll Revision Announcement a nd was o lli cia l on Decclllbel' 1, 1997. It is the leg-I I sta ndard put forth by VSP a nd enforced and followed by the FDA. The rDA has not givcn guidance ~lS to how using the second dissolution test is to be documented, whether it will be in an annllal report as any USP c hange, or by some othcr mechanism.
Dissoilltion Tecbllologiesl MA Y 1998 The two tiered test will be revised aga in to add the application to soft gelatin caps ul es. With soft gelatin caps ul es the cu rren t information suggests that a different activity of pepsin or a different concentration of pancreatin wi ll be needed. The sta ndnrd for products that arc gelati n coated tablets will also be addressed.
USP was g lad to be a part of t he efforts of the \ Vorking G roup and was pleased with the outCOIllC. It is hoped t hat this kind of inte raction invo lving USP, FDA, and industry wi ll continue.
